Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphomas

  • Natthapol Songdej
  • Eric S. Winer
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Non-Hodgkin Lymphoma is a heterogeneous group of lymphoid ­malignancies that involves mature B-cells, mature T-cells, and their progenitors. Although novel chemotherapy and immunotherapy regimens have improved rates of complete response and overall survival, autologous stem cell transplant (ASCT) is used in both the front-line and relapsed setting to further improve these markers and ­potentially cure. Even in indolent lymphomas, ASCT shows a definite ­improvement in ­progression-free survival, although no improvement in overall ­survival. The most promising results for front-line ASCT are in mantle cell lymphoma (MCL), where there is evidence of long-term progression-free and overall survival with evidence of a cured fraction. In the relapsed setting, ASCT is the standard of care in diffuse large B-cell lymphoma, though results of ASCT in the relapsed setting for MCL and Burkitt lymphoma are disappointing. The role and timing of ASCT in peripheral T-cell lymphomas are yet to be defined, but front-line ASCT in ­enteropathy-associated T-cell lymphoma and advanced-stage cutaneous T-cell lymphoma shows promise for improving long-term outcomes. Additional studies on front-line and relapsed ASCT with novel chemotherapy and immunotherapy regimens may demonstrate further improved responses and survival, especially for high-risk patients.


Follicular Lymphoma Mantle Cell Lymphoma Autologous Stem Cell Transplant Conditioning Regimen Burkitt Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Swerdlow AJ (2008) World Health Organization classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, FranceGoogle Scholar
  2. 2.
  3. 3.
    Gyan E, Foussard C, Bertrand P et al (2009) High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 113(5):995–1001PubMedCrossRefGoogle Scholar
  4. 4.
    Lenz G, Dreyling M, Schiegnitz E et al (2004) Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104(9):2667–2674PubMedCrossRefGoogle Scholar
  5. 5.
    Freeman BJ, Roberts MS, Vogler CA et al (1999) Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 94(6):2142–2150PubMedGoogle Scholar
  6. 6.
    Apostolidis J, Gupta RK, Grenzelias D et al (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18(3):527–536PubMedGoogle Scholar
  7. 7.
    Brice P, Simon D, Bouabdallah R et al (2000) High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11(12):1585–1590PubMedCrossRefGoogle Scholar
  8. 8.
    Grigg AP, Stone J, Milner AD et al (2010) Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 51(4):641–649PubMedCrossRefGoogle Scholar
  9. 9.
    Bierman PJ, Vose JM, Anderson JR et al (1997) High-dose therapy with autologous ­hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 15(2):445–450PubMedGoogle Scholar
  10. 10.
    Cao TM, Horning S, Negrin RS et al (2001) High-dose therapy and autologous ­hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University ­experience. Biol Blood Marrow Transplant 7(5):294–301PubMedCrossRefGoogle Scholar
  11. 11.
    Schouten HC, Qian W, Kvaloy S et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the ­randomized European CUP trial. J Clin Oncol 21(21):3918–3927PubMedCrossRefGoogle Scholar
  12. 12.
    Montoto S, Canals C, Rohatiner AZ et al (2007) Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 21(11):2324–2331PubMedCrossRefGoogle Scholar
  13. 13.
    Freedman AS, Gribben JG, Neuberg D et al (1996) High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88(7):2780–2786PubMedGoogle Scholar
  14. 14.
    Horning SJ, Negrin RS, Hoppe RT et al (2001) High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97(2):404–409PubMedCrossRefGoogle Scholar
  15. 15.
    Ladetto M, Corradini P, Vallet S et al (2002) High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 100(5):1559–1565PubMedCrossRefGoogle Scholar
  16. 16.
    Deconinck E, Foussard C, Milpied N et al (2005) High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105(10):3817–3823PubMedCrossRefGoogle Scholar
  17. 17.
    Sebban C, Mounier N, Brousse N et al (2006) Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood 108(8):2540–2544PubMedCrossRefGoogle Scholar
  18. 18.
    Hamadani M, Benson DM Jr, Lin TS et al (2008) High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell ­lymphoma. Eur J Haematol 81(6):425–431PubMedCrossRefGoogle Scholar
  19. 19.
    Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417–1423PubMedCrossRefGoogle Scholar
  20. 20.
    Sebban C, Brice P, Delarue R et al (2008) Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 26(21):3614–3620PubMedCrossRefGoogle Scholar
  21. 21.
    Witzens-Harig M, Dreger P (2010) Autologous transplant of follicular lymphoma in the era of rituximab. Leuk Lymphoma 51(6):967–974PubMedCrossRefGoogle Scholar
  22. 22.
    Sehn LH, Donaldson J, Filewich A et al (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171–4173PubMedCrossRefGoogle Scholar
  23. 23.
    Greb A, Bohlius J, Trelle S et al (2007) High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma—results of a comprehensive meta-analysis. Cancer Treat Rev 33(4):338–346PubMedCrossRefGoogle Scholar
  24. 24.
    Vitolo U, Chiappella A, Angelucci E et al (2009) Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 94(9):1250–1258PubMedCrossRefGoogle Scholar
  25. 25.
    Glass B, Ziepert M, Reiser M et al (2010) High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 21(11):2255–2261PubMedCrossRefGoogle Scholar
  26. 26.
    Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, Winter JN, Miller TP, Tubbs RR, Marcellus DC, Friedberg JW, Barton K, Mills GM, LeBlanc ML, Rimsa L, Forman SJ, Fisher RI (2011) Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/− R for eight cycles to CHOP +/− R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 29:8001, Meeting AbstractGoogle Scholar
  27. 27.
    Philip T, Guglielmi C, Hagenbeek A et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333(23):1540–1545PubMedCrossRefGoogle Scholar
  28. 28.
    Buadi FK, Micallef IN, Ansell SM et al (2006) Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin’s lymphoma. Bone Marrow Transplant 37(11):1017–1022PubMedCrossRefGoogle Scholar
  29. 29.
    Jantunen E, Canals C, Rambaldi A et al (2008) Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 93(12):1837–1842PubMedCrossRefGoogle Scholar
  30. 30.
    Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144–4152PubMedCrossRefGoogle Scholar
  31. 31.
    Geisler CH, Kolstad A, Laurell A et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687–2693PubMedCrossRefGoogle Scholar
  32. 32.
    Dreger P, Rieger M, Seyfarth B et al (2007) Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 92(1):42–49PubMedCrossRefGoogle Scholar
  33. 33.
    Romaguera JE, Fayad L, Rodriguez MA et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013–7023PubMedCrossRefGoogle Scholar
  34. 34.
    Jantunen E, Canals C, Attal M et al (2011) Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 23:166–171PubMedCrossRefGoogle Scholar
  35. 35.
    Sweetenham JW. Highly aggressive lymphomas in adults. Hematology/oncology clinics of North America 2008; 22(5): 965–78, ix.Google Scholar
  36. 36.
    Jost LM, Jacky E, Dommann-Scherrer C et al (1995) Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 6(5):445–451PubMedGoogle Scholar
  37. 37.
    Sweetenham JW, Pearce R, Taghipour G et al (1996) Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 14(9):2465–2472PubMedGoogle Scholar
  38. 38.
    Song KW, Barnett MJ, Gascoyne RD et al (2006) Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol 133(6):634–637PubMedCrossRefGoogle Scholar
  39. 39.
    van Imhoff GW, van der Holt B, MacKenzie MA et al (2005) Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 19(6):945–952PubMedCrossRefGoogle Scholar
  40. 40.
    Hosing C, Champlin RE (2011) Stem-cell transplantation in T-cell non-Hodgkin’s lymphomas. Ann Oncol 22:1471–1477PubMedCrossRefGoogle Scholar
  41. 41.
    Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1(1):45–50PubMedGoogle Scholar
  42. 42.
    Rodriguez J, Conde E, Gutierrez A et al (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18(4):652–657PubMedCrossRefGoogle Scholar
  43. 43.
    Duarte RF, Schmitz N, Servitje O et al (2008) Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 41(7):597–604PubMedCrossRefGoogle Scholar
  44. 44.
    Reimer P, Rudiger T, Geissinger E et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27(1):106–113PubMedCrossRefGoogle Scholar
  45. 45.
    Mercadal S, Briones J, Xicoy B et al (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958–963PubMedCrossRefGoogle Scholar
  46. 46.
    Rodriguez J, Conde E, Gutierrez A et al (2007) Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 78(4):290–296PubMedCrossRefGoogle Scholar
  47. 47.
    Feyler S, Prince HM, Pearce R et al (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 40(5):443–450PubMedCrossRefGoogle Scholar
  48. 48.
    Sieniawski M, Angamuthu N, Boyd K et al (2010) Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 115(18):3664–3670PubMedCrossRefGoogle Scholar
  49. 49.
    Al-Toma A, Verbeek WH, Hadithi M et al (2007) Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 56(10):1373–1378PubMedCrossRefGoogle Scholar
  50. 50.
    Gale J, Simmonds PD, Mead GM et al (2000) Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 18(4):795–803PubMedGoogle Scholar
  51. 51.
    Jantunen E, Juvonen E, Wiklund T et al (2003) High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 44(12):2163–2164PubMedCrossRefGoogle Scholar
  52. 52.
    Rongey C, Micallef I, Smyrk T et al (2006) Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci 51(6):1082–1086PubMedCrossRefGoogle Scholar
  53. 53.
    Al-toma A, Verbeek WH, Mulder CJ (2007) The management of complicated celiac disease. Dig Dis 25(3):230–236PubMedCrossRefGoogle Scholar
  54. 54.
    Bishton MJ, Haynes AP (2007) Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol 136(1):111–113PubMedCrossRefGoogle Scholar
  55. 55.
    Bigler RD, Crilley P, Micaily B et al (1991) Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 7(2):133–137PubMedGoogle Scholar
  56. 56.
    Olavarria E, Child F, Woolford A et al (2001) T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol 114(3):624–631PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of MedicineRhode Island Hospital, The Warren Alpert Medical School of Brown UniversityProvidenceUSA
  2. 2.Division of Hematology and OncologyRhode Island Hospital, The Warren Alpert Medical School of Brown UniversityProvidenceUSA
  3. 3.Comprehensive Cancer Center, University MedicineProvidenceUSA

Personalised recommendations